Suchergebnis - Abbildungen und Graphiken

1. Waters J; Ashford J; J�ger B; Verboom CN; Wonnacott S
Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial Of Physiotens In Combination) Study
TOPIC-Studie - Design
Journal of Clinical and Basic Cardiology 1999; 2 (2): 219-224
Study plan for TOPIC. A = placebo run-in phase (4 weeks; n = 792). B = open-label monotherapy phase (8 weeks; n = 678; moxonidine 200 mcg/day for 4 weeks, then 200 or 400 mcg/day as required). C = moxonidine monotherapy (4 weeks; n = 303; moxonidine 200 or 400 mcg/day as required for 4 weeks). D, E, F = combination therapy (4 weeks; moxonidine [400 mcg/day] plus other agent as specified below). D = moxonidine plus amlodipine (5 mg/day) (n = 87). E = moxonidine plus enalapril (10 mg/day) (n = 88). F = moxonidine plus hydrochlorothiazide (12.5 mg/day) (n = 97).

Keywords: Amlodipin, amlodipine, Design, Design, Hydrochlorothiazid, hydrochlorothiazide, Moxonidin, moxonidine, Schema, Studie, study, TOPIC, TOPIC

Artikel:
Volltext (PDF)
Summary
Abbildungen

Detailansicht